Advertisement
Mayo Clinic Proceedings Home

Open-Label Study of a Proprietary Treatment Program Targeting Type A γ-Aminobutyric Acid Receptor Dysregulation in Methamphetamine Dependence

      OBJECTIVE

      To evaluate the safety and efficacy of the pharmacological component of a proprietary medical treatment program targeting type A γ-aminobutyric acid receptor dysregulation in adults who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria for methamphetamine dependence.

      PARTICIPANTS AND METHODS

      A prospective, open-label, single-group study of the medication portion of a proprietary treatment program for methamphetamine dependence was conducted from July 1, 2005, to May 10, 2006, at Research Across America, an outpatient private, for-profit, clinical research company in Dallas, TX. In the study, flumazenil, hydroxyzine, and gabapentin, all of which were approved by the US Food and Drug Administration for indications other than drug dependence, were used off-label for the treatment of methamphetamine dependence. Fifty persons who had used methamphetamine within 7 days of study entry were enrolled and received the treatment. Treatment lasted 4 weeks, followed by 8 weeks of weekly follow-up visits to monitor for methamphetamine use via urine drug tests and self-reporting.

      RESULTS

      Participant retention was higher than expected, with 85% of participants completing the program. Significant decrease in methamphetamine use (P<.001) was noted at 84 days after vs 90 days before treatment. If missing data are counted as days of methamphetamine use, a 47% reduction in use was observed for the entire sample (P<.001) and a 65% reduction for the 36 who completed the 8-week evaluation phase (P<.001). Urine test results and self-reported use were positively correlated (Pearson r=0.72, P<.001). The frequency of cravings was reduced on average by 66% (P<.001), with 30 of 31 (97%) of the 36 who completed the study reporting reduction in cravings.

      CONCLUSION

      Substantial reductions in methamphetamine cravings and use were observed in all phases of treatment, and the retention rate of participants was high. These findings suggest that the efficacy of the medications and of the entire program in treating methamphetamine dependence should be examined in controlled trials.
      CI (confidence interval), GABA (γ-aminobutyric acid), GABAA (type A GABA), TLFB (timeline followback), UDS (urine drug screen)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Substance Abuse Mental Heath Services Administration (SAMHSA)
        Methamphetamine Use, Abuse and Dependence 2002, 2003 and 2004. US Dept of Health and Human Services, Rockville, MD2005
        • Galloway GP
        • Newmeyer J
        • Knapp T
        • Stalcup SA
        • Smith D
        Imipramine for the treatment of cocaine and methamphetamine dependence.
        J Addict Dis. 1994; 13: 201-216
        • Piasecki MP
        • Steinagel GM
        • Thienhaus OJ
        • Kohlenberg BS
        An exploratory study: the use of paroxetine for methamphetamine craving.
        J Psychoactive Drugs. 2002; 34: 301-304
        • Brodie JD
        • Figueroa E
        • Laska EM
        • Dewey SL
        Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction.
        Synapse. 2005; 55: 122-125
        • Heinzerling KG
        • Shoptaw S
        • Peck JA
        • et al.
        Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence.
        Drug Alcohol Depend. 2006 Dec 1; 85 (Epub 2006 Jun 5.): 177-184
        • Shoptaw S
        • Huber A
        • Peck J
        • et al.
        Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence.
        Drug Alcohol Depend. 2006 Oct 15; 85 (Epub 2006 Apr 18.): 12-18
        • Newton TF
        • Roache JD
        • De La Garza II, R
        • et al.
        Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving.
        Neuropsychopharmacology. 2006 Jul; 31 (Epub 2005 Nov 23.): 1537-1544
        • Vocci F
        • Ling W
        Medications development: successes and challenges.
        Pharmacol Ther. 2005; 108: 94-108
        • Volkow ND
        • Wang GJ
        • Fowler JS
        • et al.
        Enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: a PET study.
        Am J Psychiatry. 1998; 155: 200-206
        • White FJ
        • Kalivas PW
        Neuroadaptations involved in amphetamine and cocaine addiction.
        Drug Alcohol Depend. 1998; 51: 141-153
        • Ito K
        • Ohmori T
        • Abekawa T
        • Koyama T
        The role of benzodiazepine receptors in the acquisition and expression of behavioral sensitization to methamphetamine.
        Pharmacol Biochem Behav. 2000; 65: 705-710
        • McFarland K
        • Kalivas PW
        The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior.
        J Neurosci. 2001; 21: 8655-8663
        • Nestler EJ
        • Hyman SE
        • Malinka RC
        Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. McGraw-Hill Medical Publishers, New York, NY2001
        • Xi ZX
        • Ramamoorthy S
        • Shen H
        • Lake R
        • Samuvel DJ
        • Kalivas PW
        GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine.
        J Neurosci. 2003; 23: 3498-3505
        • Ke Y
        • Streeter CC
        • Nassar LE
        • et al.
        Frontal lobe GABA levels in cocaine dependence: a two-dimensional, J-resolved magnetic resonance spectroscopy study.
        Psychiatry Res. 2004; 130: 283-293
      1. Smith SS, Kemelman M, Carpov A. Chronic methamphetamine administration increases GABAA receptor 4 subunit expression in hippocampus and cortex: reversal by flumazenil treatment [poster]. Presented at: Neurobiology of Addiction (C3) Meeting; Sante Fe, NM; February 25-March 1, 2007.

        • Sanna E
        • Mostallino MC
        • Busonero F
        • et al.
        Changes in GABAA receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal.
        J Neurosci. 2003; 23: 11711-11724
        • Cagetti E
        • Liang J
        • Spigelman I
        • Olsen RW
        Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABAA receptors.
        Mol Pharmacol. 2003; 63: 53-64
        • Smith SS
        • Gong QH
        • Hsu FC
        • Markowitz RS
        • ffrench-Mullen JM
        • Li X
        GABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid.
        Nature. 1998; 392: 926-930
      2. Zhou X, Gong QH, Smith SS. Regulation of GABAA receptor α4 subunit expression in an in vitro model [program/poster 528.9/D53]. Poster presented at: 36th Annual Meeting of the Society for Neuroscience; Atlanta, GA; October 17, 2006.

        • Sills GJ
        The mechanisms of action of gabapentin and pregabalin.
        Curr Opin Pharmacol. 2006 Feb; 6 (Epub 2005 Dec 22.): 108-113
        • van Hooft JA
        • Dougherty JJ
        • Endeman D
        • Nichols RA
        • Wadman WJ
        Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex.
        Eur J Pharmacol. 2002; 449: 221-228
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. American Psychiatric Association, Washington, DC2000
        • Nazrul Islam SK
        • Jahangir Hossain K
        • Ahsan M
        Serum vitamin E, C and A status of the drug addicts undergoing detoxification: influence of drug habit, sexual practice and lifestyle factors.
        Eur J Clin Nutr. 2001; 55: 1022-1027
        • Volpicelli JR
        • Pettinati HM
        • McLellan AT
        • O'Brien CP
        Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. Guilford Press, New York, NY2001
        • Sobell LC
        • Sobell MB
        Alcohol consumption measures.
        in: Allen JP Columbus M Assessing Alcohol Problems: A Guide for Clinicians and Researchers. National Institute on Alcohol Abuse and Alcoholism, Rockville, MD1995: 55-73
        • Snedecor GW
        • Cochran WG
        Statistical Methods. 8th ed. Iowa State University Press, Ames, IA1989
        • Milliken GA
        • Johnson DE
        Analysis of Messy Data. Chapman & Hall, New York, NY1992 (Designed Experiments; vol 1.)
        • Dackis CA
        • O'Brien CP
        Cocaine dependence: a disease of the brain's reward centers.
        J Subst Abuse Treat. 2001; 21: 111-117
        • Rawson RA
        • Marinelli-Casey P
        • Anglin MD
        • et al.
        Methamphetamine Treatment Project Corporate Authors. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence.
        Addiction. 2004; 99: 708-717
        • Woody GE
        Research findings on psychotherapy of addictive disorders.
        Am J Addict. 2003; 12: S19-S26
        • Bobes J
        • McCann UD
        Developments in the treatment of drug dependence.
        Curr Opin Psychiatry. 2000; 13: 333-338
        • Maglione M
        • Chao B
        • Anglin MD
        Correlates of outpatient drug treatment drop-out among methamphetamine users.
        J Psychoactive Drugs. 2000; 32: 221-228
        • Brecht ML
        • von Mayrhauser C
        • Anglin MD
        Predictors of relapse after treatment for methamphetamine use.
        J Psychoactive Drugs. 2000; 32: 211-220
        • Bishop S
        Epidemiology and Treatment of Methamphetamine Abuse in California: A Regional Report. National Evaluation and Technical Assistance Center, Los Angeles, CA1999
        • Meredith CW
        • Jaffe C
        • Ang-Lee K
        • Saxon AJ
        Implications of chronic methamphetamine use: a literature review.
        Harv Rev Psychiatry. 2005; 13: 141-154
        • Kalechstein AD
        • Newton TF
        • Green M
        Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence.
        J Neuropsychiatry Clin Neurosci. Spring 2003; 15: 215-220
        • Maxwell JC
        Emerging research on methamphetamine.
        Curr Opin Psychiatry. 2005; 18: 235-242
        • Marlatt GA
        • Witkiewitz K
        Relapse prevention for alcohol and drug problems.
        in: Marlatt GA Donovan DM Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Disorders. Guilford Press, New York, NY2005: 1-44
        • Fillingim RB
        • Price DD
        What is controlled for in placebo-controlled trials [editorial]?.
        Mayo Clin Proc. 2005; 80: 1119-1121